Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Blood (2019) 133 (14): 1548–1559.

https://doi.org/10.1182/blood-2018-10-881961

Published: 2019

Includes: Supplemental data

Journal Articles

Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3 -ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)

Geoffrey L. Uy, MD, Sumithra Mandrekar, PhD, Kristina Laumann, Ben Sanford, Guido Marcucci, MD, Weiqiang Zhao, MD PhD, Mark J. Levis, MD PhD, Heidi D. Klepin, MD MS, Maria R. Baer, MD, Bayard L. Powell, MD, Peter Westervelt, MD PhD, Daniel J. DeAngelo, MD PhD, Wendy Stock, MD, Clara D. Bloomfield, MD, John C. Byrd, MD, Richard M. Stone, MD, Richard A. Larson, MD

Blood (2015) 126 (23): 319.

https://doi.org/10.1182/blood.V126.23.319.319

Published: 2015

Journal Articles

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Blood (2014) 124 (21): 796.

https://doi.org/10.1182/blood.V124.21.796.796

Published: 2014

Journal Articles

Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Geoffrey L. Uy, MD, Ben Sanford, Guido Marcucci, MD, Weiqiang Zhao, MD, PhD, Susan Geyer, PhD, Heidi D. Klepin, MD, MS, Bayard L. Powell, MD, Maria R. Baer, MD, Wendy Stock, M.D., Richard M. Stone, MD, Richard A. Larson, MD

Blood (2013) 122 (21): 2653.

https://doi.org/10.1182/blood.V122.21.2653.2653

Published: 2013

Journal Articles

Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Blood (2013) 122 (21): 3903.

https://doi.org/10.1182/blood.V122.21.3903.3903

Published: 2013

Journal Articles

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

William Blum, MD, Ben Sanford, Rebecca B Klisovic, MD, Daniel J. DeAngelo, MD, PhD, Geoffrey Uy, MD, Bayard L. Powell, MD, Wendy Stock, MD, Maria R. Baer, M.D., Jonathan E. Kolitz, MD, Meir Wetzler, MD, Eva Hoke, Clara D. Bloomfield, MD, Susan Geyer, PhD, Guido Marcucci, MD, Richard M. Stone, MD, Richard A. Larson, MD

Blood (2012) 120 (21): 44.

https://doi.org/10.1182/blood.V120.21.44.44

Published: 2012

Journal Articles

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).

Wendy Stock, MD, Ben Sanford, M.A., Gerard Lozanski, M.D., Ravi Vij, MD, John C. Byrd, Bayard L. Powell, MD, Meir Wetzler, MD, Dorie Sher, B.S., Colin Edwards, Ph.D., Michael Kelly, B.S., Sue Richards, Ph.D, Crystal Sung, PhD, Greg Malnassy, B.S., Eva Hoke, BA, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2009) 114 (22): 838.

https://doi.org/10.1182/blood.V114.22.838.838

Published: 2009

Journal Articles

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Wendy Stock, Mei La, Ben Sanford, Clara D. Bloomfield, James W. Vardiman, Paul Gaynon, Richard A. Larson, James Nachman

Blood (2008) 112 (5): 1646–1654.

https://doi.org/10.1182/blood-2008-01-130237

Published: 2008

Journal Articles

Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102).

Gerard Lozanski, MD, Ben Sanford, MS, Krzysztof Mrozek, MD, PhD, Colin Edwards, PhD, Rebecca Pearson, BS, Clara D. Bloomfield, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2007) 110 (11): 2386.

https://doi.org/10.1182/blood.V110.11.2386.2386

Published: 2007

Journal Articles

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.

Robert Z. Orlowski, MD, PhD, Bercedis L. Peterson, PhD, Ben Sanford, Asher A. Chanan-Khan, MD, Lee M. Zehngebot, MD, Peter R. Watson, MD, Michael A. Caligiuri, MD, Richard A. Larson, MD, the Cancer Leukemia Group B

Blood (2006) 108 (11): 797.

https://doi.org/10.1182/blood.V108.11.797.797

Published: 2006

Journal Articles

CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.

Gerard Lozanski, MD, Ben Sanford, MS, Daohai Yu, PhD, Rebecca Pearson, MLT, Colin Edwards, MS, John C. Byrd, MD, Richard A. Larson, MD, Clara D. Bloomfield, MD, Wendy Stock, MD

Blood (2006) 108 (11): 2293.

https://doi.org/10.1182/blood.V108.11.2293.2293

Published: 2006

Journal Articles

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Wendy Stock, MD, Daohai Yu, PhD, Ben Sanford, MS, Gerard Lozanski, Ph.D, Spero Cataland, MD, Ravi Vij, MD, John Byrd, MD, Bayard Powell, MD, Meir Wetzler, MD, Maher Albitar, MD, Dorie Sher, BS, Colin Edwards, MS, Eva Hoke, BS, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 145.

https://doi.org/10.1182/blood.V106.11.145.145

Published: 2005

NARROW

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3 -ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102).

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.

CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only